“Our Coral platform is designed to empower interventionalists at all skill levels not only to carry out these procedures but also to do so in a cost-efficient manner, with the goal of making certain that millions of additional sick patients who cannot be currently treated will get the life-saving intervention they need,” said Mark Barrish, CEO and co-founder of Moray Medical.
Investors included 415 CAPITAL (lead), Heal Capital, as well as a number of prominent medtech entrepreneurs, such as Fred St. Goar, M.D., inventor of the MitralClip transcatheter mitral valve repair (TMVR) system.
While the Coral platform promises to dramatically simplify a wide range of minimally invasive cardiovascular interventions, Moray Medical is initially focused on the rapidly growing TMVR market.
“There is no argument that transcatheter edge-to-edge repair (TEER), or clip therapy, is steadily evolving into the new clinical standard for heart valve repair. However, the intricacy and learning curve required by currently marketed devices means that the overwhelming majority of sick patients are not receiving treatment,” said Barrish.